12:00 AM
 | 
Nov 12, 2012
 |  BC Week In Review  |  Company News  |  Deals

DUSA, Sun Pharmaceutical deal

Sun will acquire DUSA for $8 per share in cash, or about $230 million. The price is a 38% premium to DUSA's close of $5.78 on Nov. 7,...

Read the full 116 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >